(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 18.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Mirum Pharmaceuticals's revenue in 2025 is $429,161,000.On average, 5 Wall Street analysts forecast MIRM's revenue for 2025 to be $25,398,496,481, with the lowest MIRM revenue forecast at $25,124,349,641, and the highest MIRM revenue forecast at $25,812,103,029. On average, 6 Wall Street analysts forecast MIRM's revenue for 2026 to be $30,464,511,042, with the lowest MIRM revenue forecast at $28,034,616,532, and the highest MIRM revenue forecast at $32,694,660,668.
In 2027, MIRM is forecast to generate $35,863,199,302 in revenue, with the lowest revenue forecast at $32,175,203,398 and the highest revenue forecast at $39,310,958,778.